a Department of Pharmaceutics , National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER) , Gandhinagar , India.
J Microencapsul. 2018 Jan;35(1):62-77. doi: 10.1080/02652048.2018.1425750. Epub 2018 Jan 22.
The aim of the study was to formulate a microemulsion (ME) using chitosan (CH) and the butter oil (BO) as a permeation enhancer for targeting drug to the posterior segment of the eye, via topical route. Triamcinolone acetonide (TA) was selected as the model drug since it undergoes extensive first-pass metabolism, leading to poor oral bioavailability of 23%. For optimisation of BO concentration, different ratios of TA:BO were prepared by simple physical mixing in the ratio of 1:9 to 9:1 and diffusion study was performed. MEs containing TA, TA:BO and TA CH ME were formulated by water titration method. Globule sizes of TA ME, TA:BO ME and TA CH ME were found to be 66.06 ± 0.32 nm, 78.52 ± 1.50 nm and 97.30 ± 2.50 nm, respectively. In ex vivo diffusion studies using goats eye, TA:BO ME (31.33 ± 0.46 and 33.98 ± 0.23) and TA CH ME (24.10 ± 0.41 and 27.00 ± 0.18) showed higher percentage of drug diffusion in comparison to TA ME (13.29 ± 0.41and 15.56 ± 0.34) and TA solution (8.20 ± 1.04 and 10.39 ± 0.22) in presence and in absence of vitreous humour. Fluorescence intensity of coumarin-6 (as a marker) loaded ME with BO and CH was found to be higher, confirming their role in altering membrane permeability and facilitating coumarin-6 diffusion to the posterior chamber. Overall, it was concluded that BO enhances the bioavailability of TA across the retina, thereby proving its potential as permeation enhancer in facilitating drug delivery to the posterior segment of the eye.
本研究旨在通过局部途径将壳聚糖 (CH) 和黄油油 (BO) 用作渗透增强剂,将微乳液 (ME) 递送至眼部后段,以靶向药物。选择曲安奈德 (TA) 作为模型药物,因为它经历广泛的首过代谢,导致口服生物利用度差,仅为 23%。为了优化 BO 浓度,通过简单的物理混合以 1:9 至 9:1 的比例制备不同比例的 TA:BO,并进行扩散研究。通过水滴定法制备含有 TA、TA:BO 和 TA CH ME 的 ME。发现 TA ME、TA:BO ME 和 TA CH ME 的粒径分别为 66.06 ± 0.32nm、78.52 ± 1.50nm 和 97.30 ± 2.50nm。在使用山羊眼的体外扩散研究中,与 TA ME (13.29 ± 0.41 和 15.56 ± 0.34) 和 TA 溶液 (8.20 ± 1.04 和 10.39 ± 0.22) 相比,TA:BO ME (31.33 ± 0.46 和 33.98 ± 0.23) 和 TA CH ME (24.10 ± 0.41 和 27.00 ± 0.18) 显示出更高比例的药物扩散在玻璃体液存在和不存在的情况下。发现载有 BO 和 CH 的香豆素-6(作为标记物)的 ME 的荧光强度更高,证实了它们在改变膜通透性和促进香豆素-6 扩散到后房方面的作用。总的来说,研究结果表明,BO 可提高 TA 穿过视网膜的生物利用度,从而证明其作为渗透增强剂在促进药物递送至眼部后段的潜力。
J Microencapsul. 2019-9-9
Eur J Pharm Sci. 2018-3-30
AAPS PharmSciTech. 2023-2-14
Pharmaceutics. 2021-12-31
Pharmaceutics. 2021-10-14
Drug Deliv Transl Res. 2022-1
Pharmaceutics. 2020-4-7
Nanomaterials (Basel). 2019-10-15